Royal Biologics Launches Fibri-Cell Live Cellular Cortical Fibers with Osteo-Spin Technology

Royal Biologics commenced U.S. launch of FIBRI-CELL™ Live Cellular Cortical Fiber Graft, with Osteo-Spin™ technology, to enhance traditional bone graft substitutes for orthopedic fusion. FIBRI-CELL with Osteo-Spin is designed to allow hospital systems to provide a true live cellular option for patients at a minimal cost.

Osteo-Spin delivers activated platelets, bone marrow aspirate and cortical fibers in an “ultra-hydrated” blend, creating a point of care live cellular bone graft.

Kits combine cortical fibers with accessories to “ultra-hydrate” a graft sample in a centrifugation cycle with maximum cellular content and handling ability.

Proprietary re-agents activate each patients’ platelets, initiating degranulation  Once platelets are degranulated, bioactive proteins and growth factors increase. FIBRI-CELL combines activated platelets, fibrin-gel, bone marrow aspirate concentrate and cortical fibers. The entire process is point of care with the patients’ live cells.

FIBRI-CELL complements the company’s FIBRINET™ Platelet-Rich Fibrin Matrix, acquired earlier this year from Vertical Spine. FIBRINET creates a platelet-rich fibrin membrane from a patient’s autologous blood. 

Salvatore Leo, Chief Executive Officer of Royal Biologics, said, “We now have the ability to harness the power of each patient’s cells by combining activated autologous blood platelets and bone marrow aspirate growth factors in a next-generation scaffold. Osteo-Spin™ technology presents the unique ability to capture a patient’s cells, optimizing all unique growth factors, for superior wicking and handling characteristics. Traditional hydration of allograft and autograft is now enhanced by accelerating the adherence of cells to each scaffold.”